BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12502367)

  • 1. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
    Hinschberger A; Butt S; Lelong V; Boulouard M; Dumuis A; Dauphin F; Bureau R; Pfeiffer B; Renard P; Rault S
    J Med Chem; 2003 Jan; 46(1):138-47. PubMed ID: 12502367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
    Lemaître S; Lepailleur A; Bureau R; Butt-Gueulle S; Lelong-Boulouard V; Duchatelle P; Boulouard M; Dumuis A; Daveu C; Lezoualc'h F; Pfeiffer B; Dauphin F; Rault S
    Bioorg Med Chem; 2009 Mar; 17(6):2607-22. PubMed ID: 19261477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH; Milhahn H; Eich E
    J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
    Yang D; Soulier JL; Sicsic S; Mathé-Allainmat M; Brémont B; Croci T; Cardamone R; Aureggi G; Langlois M
    J Med Chem; 1997 Feb; 40(4):608-21. PubMed ID: 9046352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
    Berque-Bestel I; Soulier JL; Giner M; Rivail L; Langlois M; Sicsic S
    J Med Chem; 2003 Jun; 46(13):2606-20. PubMed ID: 12801225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
    J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
    J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
    Moser PC; Bergis OE; Jegham S; Lochead A; Duconseille E; Terranova JP; Caille D; Berque-Bestel I; Lezoualc'h F; Fischmeister R; Dumuis A; Bockaert J; George P; Soubrié P; Scatton B
    J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
    Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
    J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
    Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
    J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
    Seong CM; Park WK; Park CM; Kong JY; Park NS
    Bioorg Med Chem Lett; 2008 Jan; 18(2):738-43. PubMed ID: 18053713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM; Thompson DC; Bloomquist WE; Susemichel AD; Calligaro DO; Cohen ML
    J Med Chem; 1998 May; 41(11):1943-55. PubMed ID: 9599243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
    J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
    J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
    Jorand-Lebrun C; Pauwels PJ; Palmier C; Moret C; Chopin P; Perez M; Marien M; Halazy S
    J Med Chem; 1997 Nov; 40(24):3974-8. PubMed ID: 9397179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.